State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China.
Faculty of Life Sciences and Medicine, King's College London School of Medicine, London, UK.
Respir Physiol Neurobiol. 2021 Sep;291:103692. doi: 10.1016/j.resp.2021.103692. Epub 2021 May 18.
A fall of ≥ 20 % in forced expiratory volume in the first second (FEV1) with a cumulative dose of histamine ≤ 7.8 μmol is considered to indicate bronchial hyperactivity, but no method exists for patients who cannot perform spirometry properly. Here we hypothesized that increases in respiratory central output measured by chest wall electromyography of the diaphragm (EMGdi-c) expressed as a function of tidal volume (EMGdi-c/VT) would have discriminative power to detect a 'positive' challenge test.
In a physiological study EMGdi was recorded from esophageal electrode (EMGdi-e) in 16 asthma patients and 16 healthy subjects during a histamine challenge test. In a second study, EMGdi from chest wall surface electrodes (EMGdi-c) was measured during a histamine challenge in 44 asthma patients and 51 healthy subjects. VT was recorded from a digital flowmeter during both studies.
With histamine challenge test the change in EMGdi-e/VT in patients with asthma was significantly higher than that in healthy subjects (104.2 % ± 48.6 % vs 0.03 % ± 17.1 %, p < 0.001). Similarly there was a significant difference in the change of EMGdi-c/VT between patients with asthma and healthy subjects (90.5 % ± 75.5 % vs 2.4 % ± 21.7 %, p < 0.001). At the optimal cut-off point (29 % increase in EMGdi-c/VT), the area under the ROC curve (AUC) for detection of a positive test was 0.91 (p < 0.001) with sensitivity 86 % and specificity 92 %.
We conclude that EMGdi-c/VT may be used as an alternative for the assessment of bronchial hypersensitivity and airway reversibility to differentiate patients with asthma from healthy subjects.
第一秒用力呼气量(FEV1)下降≥20%,组胺累积剂量≤7.8μmol 被认为表明存在支气管高反应性,但对于无法正确进行肺活量测定的患者,尚无方法可用于判断。在这里,我们假设通过膈神经胸壁肌电图(EMGdi-c)测量的呼吸中枢输出增加,以潮气量(EMGdi-c/VT)的函数表示,将具有区分“阳性”激发试验的能力。
在一项生理研究中,在组胺激发试验期间,通过食管电极(EMGdi-e)记录 16 例哮喘患者和 16 例健康受试者的 EMGdi。在第二项研究中,在 44 例哮喘患者和 51 例健康受试者的组胺激发试验期间,通过胸壁表面电极(EMGdi-c)测量 EMGdi。在两项研究中,VT 均通过数字流量计进行记录。
在组胺激发试验中,哮喘患者的 EMGdi-e/VT 变化明显高于健康受试者(104.2%±48.6%比 0.03%±17.1%,p<0.001)。同样,哮喘患者和健康受试者的 EMGdi-c/VT 变化也存在显著差异(90.5%±75.5%比 2.4%±21.7%,p<0.001)。在最佳截断点(EMGdi-c/VT 增加 29%),ROC 曲线下面积(AUC)用于检测阳性试验的 AUC 为 0.91(p<0.001),灵敏度为 86%,特异性为 92%。
我们得出结论,EMGdi-c/VT 可作为评估支气管高反应性和气道可逆性的替代指标,用于区分哮喘患者和健康受试者。